GlycoMimetics Inc (GLYC)
0.4118
+0.01
(+2.44%)
USD |
NASDAQ |
Nov 14, 16:00
0.3994
-0.01
(-3.01%)
After-Hours: 20:00
GlycoMimetics Research and Development Expense (Quarterly): 6.286M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 6.286M |
| March 31, 2024 | 6.026M |
| December 31, 2023 | 5.288M |
| September 30, 2023 | 5.292M |
| June 30, 2023 | 4.073M |
| March 31, 2023 | 5.419M |
| December 31, 2022 | 5.891M |
| September 30, 2022 | 4.923M |
| June 30, 2022 | 7.973M |
| March 31, 2022 | 9.604M |
| December 31, 2021 | 12.90M |
| September 30, 2021 | 13.28M |
| June 30, 2021 | 10.17M |
| March 31, 2021 | 11.15M |
| December 31, 2020 | 11.72M |
| September 30, 2020 | 10.67M |
| June 30, 2020 | 9.871M |
| March 31, 2020 | 12.67M |
| December 31, 2019 | 11.47M |
| September 30, 2019 | 10.72M |
| June 30, 2019 | 13.07M |
| March 31, 2019 | 11.77M |
| December 31, 2018 | 12.04M |
| September 30, 2018 | 9.729M |
| Date | Value |
|---|---|
| June 30, 2018 | 9.302M |
| March 31, 2018 | 9.021M |
| December 31, 2017 | 6.720M |
| September 30, 2017 | 5.780M |
| June 30, 2017 | 5.722M |
| March 31, 2017 | 5.878M |
| December 31, 2016 | 6.060M |
| September 30, 2016 | 5.922M |
| June 30, 2016 | 5.781M |
| March 31, 2016 | 5.519M |
| December 31, 2015 | 6.961M |
| September 30, 2015 | 5.038M |
| June 30, 2015 | 7.843M |
| March 31, 2015 | 5.208M |
| December 31, 2014 | 5.281M |
| September 30, 2014 | 5.051M |
| June 30, 2014 | 5.358M |
| March 31, 2014 | 3.882M |
| December 31, 2013 | 3.122M |
| September 30, 2013 | 2.953M |
| June 30, 2013 | 2.884M |
| March 31, 2013 | 2.743M |
| December 31, 2012 | 2.730M |
| September 30, 2012 | 2.452M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
4.073M
Minimum
Jun 2023
13.28M
Maximum
Sep 2021
8.666M
Average
9.604M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 184.90M |
| Arbutus Biopharma Corp | 14.27M |
| Revance Therapeutics Inc | 11.38M |
| FibroGen Inc | 34.11M |
| Cidara Therapeutics Inc | 12.43M |